MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 1.8% - Still a Buy?

Key Points

• MAIA Biotechnology's stock price increased by 1.8% on Monday, trading between $1.68 and $1.73 during the day, with approximately 386,694 shares exchanged.
• Institutional investors have recently made significant moves in MAIA, with Centric Wealth Management increasing its position by 740.2%, now holding shares valued at over $1 million.
• MAIA Biotechnology is a clinical stage company developing a cancer treatment called THIO, which is currently in a Phase II clinical study for non-small cell lung cancer.

Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) were up 1.8% during mid-day trading on Monday . The company traded as high as $1.73 and last traded at $1.71. Approximately 386,694 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 445,497 shares. The stock had previously closed at $1.68.

MAIA Biotechnology Stock Down 1.3%

The business has a 50-day moving average price of $1.60 and a 200-day moving average price of $1.71. The firm has a market capitalization of $51.13 million, a PE ratio of -2.72 and a beta of 0.01.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Centerpoint Advisory Group purchased a new position in shares of MAIA Biotechnology during the second quarter worth about $28,000. Marshall Wace LLP purchased a new position in shares of MAIA Biotechnology during the second quarter worth about $29,000. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology during the second quarter worth about $52,000. Geode Capital Management LLC grew its holdings in shares of MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock worth $400,000 after buying an additional 7,746 shares during the last quarter. Finally, Centric Wealth Management grew its holdings in shares of MAIA Biotechnology by 740.2% during the second quarter. Centric Wealth Management now owns 573,398 shares of the company's stock worth $1,032,000 after buying an additional 505,150 shares during the last quarter. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.